FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Wool Kyle Michael 2. Issuer Name and Ticker or Trading Symbol AIkido Pharma Inc. [ AIKI ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)
ONE ROCKEFELLER PLAZA 11TH FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)
12/8/2022
(Street)
NEW YORK, NY 10020
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  12/8/2022    P    5000  A $3.562  255822 (1) D   
Common Stock                 1477 (2) I  Catatonk Creek LLC 
Common Stock                 1476 (2) I  Tioga 22 LLC 
Common Stock                 3559 (3) I  Wool c/f Alison Cottone UTMA/NY Age 18 
Common Stock                 1477 (4) I  Dongam, LLC 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Of the 255,822 shares reported as beneficially owned directly, 173,598 shares are beneficially owned directly by Mr. Wool and 82,224 shares are beneficially owned directly by Ms. Yu.
(2)  Mr. Wool is the sole member of Catatonk Creek, LLC and Tioga 22, LLC.
(3)  Mr. Wool controls this UTMA account until Ms. Cottone is 18 years old.
(4)  Ms. Yu is the sole member of Dongam, LLC.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Wool Kyle Michael
ONE ROCKEFELLER PLAZA 11TH FLOOR
NEW YORK, NY 10020
X


Yu Soo
ONE ROCKEFELLER PLAZA 11TH FLOOR
NEW YORK, NY 10020
X



Signatures
/s/ Kyle Wool 12/12/2022
**Signature of Reporting Person Date
/s/ Soo Yu 12/12/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more Alkido Pharma Charts.
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more Alkido Pharma Charts.